Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linaprazan Glurate DDI and H. pylori Eradication Study
NCT07294846Phase 1Completed
- Sponsor
- Jiangsu Sinorda Biomedicine Co., Ltd.
- Start
- Sep 2025
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of linaprazan glurate in Helicobacter pylori infection, sponsored by Jiangsu Sinorda Biomedicine Co., Ltd. Primary endpoints: Steady state maximum concentration at 7 days, Area under the drug-time curve within the dosing interval after reaching steady state at 7 days and 8 more. Started Sep 2025; status: completed.
02
Drugs
linaprazan glurate
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT07294846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07294846.